About Nexien BioPharma
Nexien BioPharma is a publicly listed company based in Denver (United States) founded in 1952 by Richard S Greenberg. Cannabis-based medical products are developed for treating various conditions. It operates on a Professional Services, Licensing Model, and HealthTech model. Nexien BioPharma has completed 1 acquisition, including CRX Bio. Its chief executive, as recorded, is Richard S Greenberg. Nexien BioPharma offers products and services including Cannabinoid Medications, Delivery Systems, and Investment in Cannabinoid Research. Its focus areas include Pharmaceuticals and Cannabinoid-Based Drugs. Its legal entity is Nexien BioPharma Inc. Its competitors include Holistic Industries, Vertosa and FarmaceuticalRX; 3 of its 3 listed competitors have raised funding.
Company details
Nexien BioPharma is focused on the research and development of cannabinoid-based pharmaceuticals in compliance with United States Food and Drug Administration (FDA) regulatory pathways. Operations are conducted with DEA-licensed clinical research organizations, contract manufacturing partners, and academic institutions. The company pursues three synergistic paths: developing and licensing cannabinoid medications for specific medical conditions, creating proprietary delivery systems for accurate dosing, and investing in cannabinoid research technologies through special purpose vehicles. Activities are centered in the healthcare sector with an emphasis on innovative drug solutions.
- Headquarters Denver, United States
- Founders Richard S Greenberg
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nexienbiopharma.com
- Social LinkedIn X Facebook
- Legal Name Nexien Biopharma, Inc.
- Net Profit-$239.11 K (USD)33.93as on Jun 30, 2024
- EBITDA-$155.66 K (USD)44.92as on Jun 30, 2024
- Latest Funding Round$1.4M (USD), Post-IPO
Nov 2017
- Investments & Acquisitions
Products & Services of Nexien BioPharma
Nexien BioPharma offers a comprehensive portfolio of products and services, including Cannabinoid Medications, Delivery Systems, and Investment in Cannabinoid Research.
Cannabinoid-based drugs are developed for medical conditions.
Proprietary systems are created for cannabinoid medication delivery.
Investments are made in cannabinoid research technologies.
Funding Insights of Nexien BioPharma
- Total Rounds 1
- Last Round Post-IPO — $1.4M
- First Round $1.4M
(Nov 2017)
All 1 funding rounds of Nexien BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $1.4M | Post-IPO | – | – | – |
People of Nexien BioPharma
18 people are tracked at Nexien BioPharma (4 in leadership, 14 in team).
| Name | Role | Group |
|---|---|---|
Richard S Greenberg | Founder & CEO | Leadership |
Evan Wasoff | Chief Financial Officer | Leadership |
Wilson Han | Chief Technology Officer | Leadership |
Kwangjin (KJ) Suk | Director of Business Planning & Strategy | New Business Development | Analytics Enablement | Leadership |
Tae Joon Song | Division Lead | Team |
Junho Kim | Production Manager | Team |
Kay K. | Business Project Manager | Team |
Joohyun Park | Project Manager | Team |
Jangwon Suh | Regional Business Manager | Team |
Eric Lee | Sr. Recruiter | Team |
Robert I. Goldfarb | General Counsel | Team |
James Parker | Low Voltage Project Manager | Team |
Jack Lee | IT Infrastructure Architect | Team |
Jueun Lee | Recruiter | Team |
Marzell Tabourne | Installation And Maintenance Engineer | Team |
Jessica Kim | Senior Recruiting Manager | Team |
Jessica Cho | Senior Recruiter | Team |
Amin Said | Mechanical Engineer | Team |
Complete people profiles for Nexien BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Nexien BioPharma
Nexien BioPharma is a publicly listed company on the OTC with ticker symbol NXEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Jul 2001
- Listed onOTC: NXEN
- Listed entityNexien BioPharma, Inc.
- Exchange sectorHealth technology
- ISINUS65343D1000
- Share price$0.00 · 2026-10-06
- Market capitalisation$7,077.22
- Volume (last session)20,161
Financials of Nexien BioPharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$239,110 | -$155,660 | |
| 2023 | -$361,900 | -$282,610 | |
| 2022 | -$626,360 | -$340,740 | |
| 2021 | -$1.9M | -$750,100 | |
| 2020 | -$2.7M | -$242,720 |
Detailed financial statements for Nexien BioPharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nexien BioPharma
Nexien BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CRX Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Cannabis research and development services are provided to clients. | crxbio.com | Denver, United States | 2017 | Oct 2018 | •••• |
Complete acquisition details for Nexien BioPharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Nexien BioPharma
4 dated milestones of Nexien BioPharma across 66 years, from founding to its latest funding, stage changes and deals.
- Founded Nexien BioPharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.4M.
- Acquisition Acquires CRX Bio.
Competitors of Nexien BioPharma
Nexien BioPharma has 3 listed competitors in our database, 3 of them funded. They include Holistic Industries, Vertosa and FarmaceuticalRX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| holisticindustries.com | 2014 | Maryland Heights, United States | $156M | 557 | Proprietary medical cannabis strains are developed and offered. | |
| vertosa.com | 2013 | Oakland, United States | $6M | Technology for active ingredients from infused hemp is provided. | ||
| farmaceuticalrx.com | 2013 | Farrell, United States | $22.94M | Cannabis-based products including flower and concentrates are manufactured and supplied. |
Detailed competitors of Nexien BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cannabis Health Tech Ecosystem
3 companies that operate in the same segment as Nexien BioPharma (Cannabis Health Tech Ecosystem) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Online marketplace platform for cannabis traders | 2015 | New York, New York, United States | USD 195.4 M | |||
Loyalty and marketing solutions for cannabis dispensaries are provided. | 2012 | West Palm Beach, Florida, United States | USD 25.79 M | USD 22.83 M | ||
An online marketplace for cannabis products is operated. | 2017 | Bend, Oregon, United States | USD 603 M | 469 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nexien Biopharma
Complete news archive for Nexien BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nexien BioPharma
Nexien BioPharma was founded in 1952 and raised its 1st funding round 65 years after it was founded.
Nexien BioPharma is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.
Richard S Greenberg is the CEO of Nexien BioPharma, as recorded in our data. They have also founded this company.
Nexien BioPharma is focused on the research and development of cannabinoid-based pharmaceuticals in compliance with United States Food and Drug Administration (FDA) regulatory pathways. Operations are conducted with DEA-licensed clinical research organizations, contract manufacturing partners, and academic institutions. The company pursues three synergistic paths: developing and licensing cannabinoid medications for specific medical conditions, creating proprietary delivery systems for accurate dosing, and investing in cannabinoid research technologies through special purpose vehicles. Activities are centered in the healthcare sector with an emphasis on innovative drug solutions.
Nexien BioPharma's top competitors include Holistic Industries, FarmaceuticalRX and Vertosa.
Nexien BioPharma offers Cannabinoid Medications, Delivery Systems, and Investment in Cannabinoid Research.
Yes, Nexien BioPharma is publicly traded on OTC under the ticker symbol NXEN.
Nexien BioPharma has made 1 acquisition, including CRX Bio.
Nexien BioPharma operates through Nexien Biopharma Inc.